Delcath Systems earnings release, August 6, 2026

Delcath Systems, Inc. (DCTH) · Form 8-K, Item 2.02 · Filed · SEC filing

Delcath Systems Reports Second Quarter 2026

Results and Business Highlights

Increases 2026 Revenue Guidance to a Range of $104M to $108M

Conference Call Today at 8:30 a.m. Eastern Time

QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results

• Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025

◦ HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025

◦ CHEMOSAT® revenue of $2.0 million, compared to $1.7 million in the second quarter of 2025

• Gross margins of 90%, compared to 86% in the second quarter of 2025

• Net income of $2.7 million for both second quarters in 2026 and 2025

• Non-GAAP adjusted EBITDA of $7.6 million, compared to $9.8 million in the second quarter of 2025

• Cash provided by operations of $5.7 million in the quarter; compared to $7.3 million in the second quarter of 2025

• Cash and investments of $95.9 million as of June 30, 2026

Business Highlights

• Currently 31 active treatment centers

• Approximately 30% growth in HEPZATO volume in the second quarter 2026 compared to the second quarter 2025

• Independent investigators presented retrospective data at ESMO Breast Cancer 2026 showing a 60% hepatic partial response rate with percutaneous hepatic perfusion in heavily pretreated patients with liver-dominant metastatic breast cancer

• Independent investigators presented two investigator-initiated Trials-in-Progress abstracts at ASCO 2026: one evaluating sequential HEPZATO followed by tebentafusp in metastatic uveal melanoma, and one evaluating HEPZATO in combination with nivolumab/relatlimab in metastatic cutaneous melanoma with liver metastases

• Dosed the first patient in the global Phase 2 trial of HEPZATO in combination with standard of care in patients with liver-dominant HER2-negative metastatic breast cancer

“Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma. The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer.”¹

Exhibit 99.1

2026 Full Year Financial Guidance

The Company’s financial outlook for fiscal year 2026:

• Total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million, reflecting an increase in HEPZATO KIT volume of at least 28% over 2025

• Full year gross margins in the range of 86% to 89%

• Positive adjusted EBITDA

Second Quarter 2026 Results

Total revenue for the quarter ending June 30, 2026 was $29.1 million compared to $24.2 million for the same period in the prior year. Revenue in the quarter includes sales of $27.1 million of HEPZATO in the U.S. and $2.0 million of CHEMOSAT in Europe.

Research and development expenses for the quarter ending June 30, 2026, were $10.4 million compared to $6.9 million for the same period in the prior year. The increase is primarily due to increased clinical headcount and increased clinical trial activity.

Selling, general and administrative expenses for the quarter ended June 30, 2026, were $13.4 million compared to $11.4 million for the same period in the prior year. The increase is primarily due to continued commercial expansion activities.

Net income was $2.7 million for both the quarters ended June 30, 2026 and June 30, 2025.

Non-GAAP adjusted EBITDA for the quarter ended June 30, 2026 was $7.6 million compared to adjusted EBITDA of $9.8 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

As of June 30, 2026, the Company had $95.9 million in cash and investments, and no debt.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

Event Date: Thursday, August 6, 2026

Time: 8:30 AM Eastern Time

Participant Numbers:

Toll Free: 1-800-717-1738

International: 1-646-307-1865

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767384&tp_key=cbc23b55c8

A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website https://investors.delcath.com/news-events/events-and-presentations.

GAAP v. Non-GAAP Measures... (truncated)ith GAAP.²

Exhibit 99.1

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’ s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Financial statements

Income Statement

Three months ended June 30, — (in thousands, except share and per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Product revenue29,13324,15654,12743,940
Cost of goods sold-2,985-3,318-6,721-6,163
Gross profit26,14820,83847,40637,777
Operating expenses:Research and development expenses10,3806,88220,20411,889
Operating expenses:Selling, general and administrative expenses13,37311,36626,44422,656
Operating expenses:Total operating expenses23,75318,24846,64834,545
Operating expenses:Operating income2,3952,5907583,232
Operating expenses:Interest income7816491,5681,267
Operating expenses:Other expense-17-34-75-30
Operating expenses:Income before income taxes3,1593,2052,2514,469
Operating expenses:Income tax expense491508653703
Operating expenses:Net income2,6682,6971,5983,766
Other comprehensive income:Unrealized gain on investments adjustments-29557-250296
Other comprehensive income:Foreign currency translation adjustments-18154-67214
Other comprehensive income:Total comprehensive income2,3552,9081,2814,276
Common share data:Basic income per common share0.070.080.040.11
Common share data:Weighted average number of basic shares outstanding35,891,91535,786,81335,956,20535,217,887
Common share data:Diluted income per common share0.070.070.040.09
Common share data:Weighted average number of dilutive shares outstanding39,761,48040,262,76439,584,32939,890,102

Income Statement

Three months ended June 30, — (in thousands)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Net income2,6682,6971,5983,766
Stock-based compensation expense5,1187,20910,06414,072
Depreciation1135121594
Interest income-781-649-1,568-1,267
Income tax expense491508653703
Adjusted EBITDA (Non-GAAP)7,6099,81610,96217,368

Balance Sheet

(in thousands, except share and per share data)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents47,52143,454
Current assetsShort-term investments48,38147,582
Current assetsAccounts receivable15,94211,744
Current assetsInventories11,71310,252
Current assetsPrepaid expenses and other current assets6,9796,498
Current assetsTotal current assets130,536119,530
Current assetsProperty, plant and equipment, net4,0193,166
Current assetsRight-of-use assets2,463936
Current assetsTotal assets137,018123,632
Current liabilitiesAccounts payable4,0112,658
Current liabilitiesAccrued expenses9,0728,191
Current liabilitiesLease liabilities, current196101
Current liabilitiesTotal current liabilities13,27910,950
Current liabilitiesLease liabilities, non-current2,267835
Current liabilitiesOther liabilities, non-current327628
Current liabilitiesTotal liabilities15,87312,413
Stockholders’ equityCommon stock, $0.01 par value; 80,000,000 shares authorized; 34,636,252 shares and 34,691,671 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively346347
Stockholders’ equityAdditional paid-in capital647,791639,145
Stockholders’ equityAccumulated deficit-527,250-528,848
Stockholders’ equityAccumulated other comprehensive income258575
Stockholders’ equityTotal stockholders’ equity121,145111,219
Stockholders’ equityTotal liabilities and stockholders’ equity137,018123,632
Full release

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company’s statements regarding the possible synergy seen in the successful Phase 2 CHOPIN Trial being transferable to clinical practice; Company’s 2026 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company’s filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Investor Relations Contact:

ICR Healthcare investorrelations@delcath.com³

Exhibit 99.1

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)⁴

Exhibit 99.1

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

(in thousands, except share and per share data)

DELCATH SYSTEMS, INC.

Reconciliation of Reported Net Income (GAAP) to Adjusted EBITDA (NON-GAAP Measure)

(Unaudited)

(in thousands)⁵

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Delcath Systems earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.